CellBion Co., Ltd. (KOSDAQ:308430)
14,900
-1,070 (-6.70%)
At close: Jun 26, 2026
CellBion Revenue
CellBion had revenue of 612.53M KRW in the quarter ending March 31, 2026, with 27.72% growth. This brings the company's revenue in the last twelve months to 2.08B, down -19.08% year-over-year. In the year 2025, CellBion had annual revenue of 1.95B, down -15.05%.
Revenue (ttm)
2.08B
Revenue Growth
-19.08%
P/S Ratio
106.88
Revenue / Employee
37.78M
Employees
55
Market Cap
222.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.95B | -344.73M | -15.05% |
| Dec 31, 2024 | 2.29B | 818.55M | 55.64% |
| Dec 31, 2023 | 1.47B | -291.63M | -16.54% |
| Dec 31, 2022 | 1.76B | 846.00M | 92.27% |
| Dec 31, 2021 | 916.88M | -443.71M | -32.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| Cosmax Nbt | 308.56B |
| Kyung Dong Pharmaceutical | 198.27B |
| GC WellBeing | 179.05B |
| DAE HWA Pharmaceutical | 143.42B |
| High Tech Pharm | 69.05B |
| Vivozon Pharmaceutical | 54.86B |
| HEM Pharma | 14.41B |